Opinion
Video
Patient Experiences, Key Clinical Trial Outcomes of the Port Delivery System
Panelists discuss how the Port Delivery System (PDS) presents important considerations around adverse effects, patient selection criteria, and adoption challenges including surgical requirements and cost-benefit analyses that must be carefully weighed when integrating this technology into retinal practice.
Video content above is prompted by the following:
- Could you discuss the key outcomes from the ARCHWAY trial for PDS?
- The PDS Q24W was noninferior to monthly ranibizumab in terms of BCVA change from baseline
Related Videos
Related Content
